Greetings from New Zealand! I hope you're doing well.
Since my last email about our biotech startup, Kimer Med, we've made tremendous progress. I thought you might be interested in hearing our most recent news: we successfully closed our seed funding round. This will enable us to greatly expand the scope and speed of development of our broad-spectrum antiviral drug.
If you're interested in following our work on a regular basis, you can sign-up for our subscriber email list here:
We also have a discussion forum: